Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Key Points
Key points are not available for this paper at this time.
Abstract
Cancer Research UK, Department of Health, and the National Institute for Health Research Cancer Research Network.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial | Synapse